<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03982797</url>
  </required_header>
  <id_info>
    <org_study_id>ENCORE-01</org_study_id>
    <secondary_id>2017-002928-24</secondary_id>
    <nct_id>NCT03982797</nct_id>
  </id_info>
  <brief_title>Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis</brief_title>
  <official_title>Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis of Recurrence and Progression.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biofabri, S.L</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación para la Investigación en Urología (FIU)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biofabri, S.L</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bladder cancer is the fourth reason of neoplasia in our environment, there are 25 new cases
      diagnosed per 100,000 inhabitants each year. To decrease the recurrence there are two
      standardized treatments: Mitomycin as chemotherapy drug and BCG *Bacile Calmette-Guérin&quot; as
      immunotherapy drug.

      BCG Moreau strain is not authorized by AEMPS, it was developed in Brazil and this country has
      extensive experience in treatment of non-muscle invasive bladder cancer with BCG Moreau, also
      BCG Moreau Rio de Janeiro make same immunological reaction as TICE, but with less adverse
      events. Thus, BCG Moreau RJ treatment could be used more time than TICE with the same dose,
      keeping immunologic status and better prophylaxis of recurrence or progression results for
      the patient.

      Each patient will be instillated via transurethral each time with 80 mg of IMUNO BCG Moreau
      RJ. There are 15 instillations during the clinical trial, 6 instillations on induction phase
      and 9 will be performed during maintaince phase.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2019</start_date>
  <completion_date type="Anticipated">March 3, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 3, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>24 months</time_frame>
    <description>The primary objective is to assessment the progression-free survival of patients diagnosed with high-risk non-muscle invasive bladder tumors treated with IMUNO BCG Moreau RJ adjuvant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival.</measure>
    <time_frame>24 months</time_frame>
    <description>The secondary objective is to assessment the disease-free survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the quality of life</measure>
    <time_frame>24 months</time_frame>
    <description>Assessment will be measure with FACT-BL version4th</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of adverse reactions</measure>
    <time_frame>24 months</time_frame>
    <description>Assessment will be measure in number and relation with IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the dropout rate due to toxicity</measure>
    <time_frame>24 months</time_frame>
    <description>Assessment will be measure in number</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">306</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>treated with IMUNO BCG Moreau RJ adjuvant.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Instillation of IMUNO BCG Moreau RJ</intervention_name>
    <description>Instillation in bladder will be done once per week during first six weeks after inclusion, and 3 instillations (one per week) on month three, another three on moth six and last three on month twelve .</description>
    <arm_group_label>treated with IMUNO BCG Moreau RJ adjuvant.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signature of the informed consent before any activity related to the study, including
             the necessary evaluations for the selection.

          2. Age between 18 and 80 years at the time of signing the informed consent.

          3. Urothelial tumor.

          4. High risk non-muscle invasive bladder tumor (defined as Ta-T1 and GIIb or GIII)
             diagnosed de novo or relapsed with or without associated in situ carcinoma. or
             carcinoma in situ isolated without visible tumor.

          5. Patient with risk of recurrence or progression greater than or equal to 10 points,
             according to CUETO tables.

        Exclusion Criteria:

          1. No muscle layer in pathological examination piece's.

          2. Non-urothelial tumor.

          3. Active cancer in any other location.

          4. Diagnosis of any other pathology that in the opinion of the researcher may increase
             the risk of the subject or reduce the chances of obtaining satisfactory data to
             achieve the objectives of the study, including the consumption of alcohol or any other
             drug.

          5. Administration of BCG in the last year before signing the informed consent. 6. BCG
             instillation contraindication during more than 15 days for any cause such as low
             bladder capacity, urinary infection, hematuria, etc.

        7. Impossibility of performing a second transurethral resection (ReRTU) between 4 and 8
        weeks after the first.

        8. Inability to start treatment within the first 4 weeks after the second transurethral
        resection (ReRTU).

        9. Participation in another clinical study where they received a research drug in the 6
        months prior to signing the informed consent.

        10. Woman considered potentially fertile. Following the Clinical Trial Facilitation Group
        (CTFG) recommendations, a woman is considered childbearing potential (WOCBP), following
        menarche and until becoming post-menopausal unless permanently sterile. Permanent
        sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral
        oophorectomy. A postmenopausal state is defined as no menses for 12 months without an
        alternative medical cause.

        11. Patients with difficulties to perform the follow-up visits established in the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Unda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Basurto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ingrid Murillo, MSc.</last_name>
    <phone>0034986330400</phone>
    <email>ingrid.murillo@biofabri.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sara Barja, MSc.</last_name>
    <phone>0034986330400</phone>
    <email>sara.barja@biofabri.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Basurto</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Puerta Del Mar</name>
      <address>
        <city>Cadiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario A Coruña</name>
      <address>
        <city>Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Venancio Chantada Abal, MD</last_name>
      <email>vchantada@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Venancio Chantada Abal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Regional Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de Las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Puche Sanz, MD</last_name>
      <email>nacho.puchesanz@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ignacio Puche Sanz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Médico Quirúrjico de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Especialidades de Jerez de La Frontera</name>
      <address>
        <city>Jerez de la Frontera</city>
        <zip>11408</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joaquín Carballido Rodríguez, MD</last_name>
      <email>carballidojoaquin@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Joaquín Carballido Rodríguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Regional de Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlos Bautista Vidal, MD</last_name>
      <email>yenyebaru@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Carlos Bautista Vidal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jesús Maria Fernández Gómez, MD</last_name>
      <email>jmfergomez@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jesús Maria Fernández Gómez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Felipe Villacampa Aubá, MD</last_name>
      <email>fvauba@unav.es</email>
    </contact>
    <investigator>
      <last_name>Felipe Villacampa Aubá, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Ramón Cortiñas González, MD</last_name>
      <email>jrcorti@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jose Ramón Cortiñas González, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 7, 2019</study_first_submitted>
  <study_first_submitted_qc>June 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2019</study_first_posted>
  <last_update_submitted>June 10, 2019</last_update_submitted>
  <last_update_submitted_qc>June 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-muscle invasive bladder tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

